Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.

Large neutral amino acids (LNAAs), including phenylalanine (Phe), compete for transport across the blood-brain barrier (BBB) via the L-type amino acid carrier. Accordingly, elevated plasma Phe impairs brain uptake of other LNAAs in patients with phenylketonuria (PKU). Direct effects of elevated brain Phe and depleted LNAAs are probably major causes for disturbed brain development and function in PKU. Competition for the carrier might conversely be put to use to lower Phe influx when the plasma concentrations of all other LNAAs are increased. This hypothesis was tested by measuring brain Phe in patients with PKU by quantitative 1H magnetic resonance spectroscopy during an oral Phe challenge with and without additional supplementation with all other LNAAs. Baseline plasma Phe was approximately 1,000 micromol/l and brain Phe was approximately 250 micromol/l in both series. Without LNAA supplementation, brain Phe increased to approximately 400 micromol/l after the oral Phe load. Electroencephalogram (EEG) spectral analysis revealed acutely disturbed brain activity. With concurrent LNAA supplementation, Phe influx was completely blocked and there was no slowing of EEG activity. These results are relevant for further characterization of the LNAA carrier and of the pathophysiology underlying brain dysfunction in PKU and for treatment of patients with PKU, as brain function might be improved by continued LNAA supplementation.

[1]  C Boesch,et al.  Versatile frequency domain fitting using time domain models and prior knowledge , 1998, Magnetic resonance in medicine.

[2]  J. Gerrard,et al.  The Influence of Phenylalanine Intake on the Chemistry and Behaviour of a Phenylketonuria Child , 1954, Acta paediatrica.

[3]  R. Kreis.  Quantitative localized 1H MR spectroscopy for clinical use , 1997 .

[4]  R. Kreis,et al.  Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. , 1996, Radiology.

[5]  M. Seashore,et al.  In Vivo Measurement of Phenylalanine in Human Brain by Proton Nuclear Magnetic Resonance Spectroscopy , 1995, Pediatric Research.

[6]  T. Johnson,et al.  The effects of chronic hyperphenylalaninaemia on mouse brain protein synthesis can be prevented by other amino acids. , 1982, The Biochemical journal.

[7]  E. Reynolds,et al.  ONE DRUG (PHENYTOIN) IN TREATMENT OF EPILEPSY , 1976, The Lancet.

[8]  R. Egeler,et al.  Langerhans cell histiocytosis. , 1995, The Journal of pediatrics.

[9]  P. Burgard,et al.  Psychiatric disorders in adult patients with early-treated phenylketonuria. , 1997, Pediatrics.

[10]  Timothy M. DeLorey,et al.  GABA and Glycine , 1999 .

[11]  The Dynamics of Brain Concentrations of Phenylalanine and Its Clinical Significance in Patients with Phenylketonuria Determined by in Vivo H Magnetic Resonance Spectroscopy , 1995, Pediatric Research.

[12]  O B Paulson,et al.  Asymmetrical Transport of Amino Acids across the Blood—Brain Barrier in Humans , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy. , 1995, Journal of magnetic resonance. Series B.

[14]  V. Neuhoff,et al.  Amino acid depletion in the blood and brain tissue of hyperphenylalaninemic rats is abolished by the administration of additional lysine: a contribution to the understanding of the metabolic defects in phenylketonuria. , 1985, Biochemical Medicine.

[15]  T. Maekawa,et al.  Excitatory Amino Acid Neurotransmitters in Human Cerebrospinal Fluid After Cardiopulmonary Resuscitation , 1994 .

[16]  L. Sonneville,et al.  EEGs IN PHENYLKETONURIA I: FOLLOW‐UP TO ADULTHOOD; II: SHORT‐TERM DIET‐RELATED CHANGES IN EEGs AND COGNITIVE FUNCTION , 1993, Developmental medicine and child neurology.

[17]  W. Pardridge,et al.  Phenylalanine transport at the human blood-brain barrier. Studies with isolated human brain capillaries. , 1986, The Journal of biological chemistry.

[18]  R. L. Brunner,et al.  Valine, isoleucine, and leucine. A new treatment for phenylketonuria. , 1990, American journal of diseases of children.

[19]  R. Wurtman,et al.  Dietary Phenylalanine and Brain Function , 1988, Birkhäuser Boston.

[20]  D. Freides,et al.  Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. , 1985, The Journal of clinical investigation.

[21]  P. Guldberg,et al.  A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. , 1998, American journal of human genetics.

[22]  M. Bofinger,et al.  Reduction of Cerebrospinal Fluid Phenylalanine after Oral Administration of Valine, Isoleucine, and Leucine , 1982, Pediatric Research.

[23]  U. Bick,et al.  Kinetics of phenylalanine transport at the human blood–brain barrier investigated in vivo , 1997, Brain Research.

[24]  S. Rapoport,et al.  Kinetics of Neutral Amino Acid Transport Across the Blood‐Brain Barrier , 1987, Journal of neurochemistry.

[25]  W H Oldendorf,et al.  Kinetic analysis of blood-brain barrier transport of amino acids. , 1975, Biochimica et biophysica acta.

[26]  C. Vorhees,et al.  Branched Chain Amino Acids Improve Complex Maze Learning in Rat Offspring Prenatally Exposed to Hyperphenylalaninemia: Implications for Maternal Phenylketonuria , 1989, Pediatric Research.

[27]  R. Kreis,et al.  Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy. , 1995, Journal of magnetic resonance. Series B.

[28]  N. Leslie,et al.  Early-treated phenylketonuria: adult neuropsychologic outcome. , 1994, The Journal of pediatrics.

[29]  B. Agranoff,et al.  Inhibition of Neutral Amino Acid Transport Across the Human Blood‐Brain Barrier by Phenylalanine , 1995, Journal of neurochemistry.

[30]  R. Surtees,et al.  RECOMMENDATIONS ON THE DIETARY-MANAGEMENT OF PHENYLKETONURIA , 1993 .

[31]  W. Oldendorf,et al.  Kinetic Constants for Blood—Brain Barrier Amino Acid Transport in Conscious Rats , 1985, Journal of neurochemistry.

[32]  H. Lou.  LARGE DOSES OF TRYPTOPHAN AND TYROSINE AS POTENTIAL THERAPEUTIC ALTERNATIVE TO DIETARY PHENYLALANINE RESTRICTION IN PHENYLKETONURIA , 1985, The Lancet.

[33]  R. Gruetter,et al.  1H NMR Studies of Glucose Transport in the Human Brain , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  L. D. de Sonneville,et al.  Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. , 1995, The Journal of pediatrics.

[35]  W. Pardridge,et al.  Neutral amino acid transport at the human blood-brain barrier. , 1988, The Journal of biological chemistry.

[36]  C. Epstein,et al.  Phenylalanine Alters the Mean Power Frequency of Electroencephalograms and Plasma L-DOPA in Treated Patients with Phenylketonuria , 1986, Pediatric Research.

[37]  J. Dancis,et al.  Two Mechanisms for IgG Uptake in Cultured Human Trophoblast: Evidence for a Novel High Affinity Fc Receptor , 1995, Pediatric Research.

[38]  B. Pennington,et al.  Neuropsychology of early-treated phenylketonuria: specific executive function deficits. , 1990, Child development.

[39]  C. Giménez,et al.  Inhibition by l‐Phenylalanine of Tyrosine Transport by Synaptosomal Plasma Membrane Vesicles: Implications in the Pathogenesis of Phenylketonuria , 1982, Journal of neurochemistry.

[40]  S. Kaufman.  Phenylketonuria: Biochemical Mechanisms , 1977 .